Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variable semaglutide dosing and timing for obesity with suboptimal response
MOH_2024-12-16_013794Phase 2Not yet recruiting
- Sponsor
- ד"ר טל סיגאווי
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaglutide in obesity, sponsored by ד"ר טל סיגאווי. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on MOH_2024-12-16_013794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-12-16_013794.